ArticleEuropean radiology2025
MR elastography-based prediction of development of hepatocellular carcinoma in patients with chronic hepatitis B with sustained virological response.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
objectivesThe goal of this study was to develop a risk score based on MR elastography (MRE) to predict hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB). MATERIALS AND
methodsA total of 345 patients with CHB who underwent 2D/3D MRE between July 2015 and December 2018 were enrolled and then randomly assigned to training (n = 243) and validation (n = 102) cohorts. An MRE-based HCC risk score was developed for the prediction of HCC development based on a multivariable Cox model and compared with previous clinical scores. The predictive performance was evaluated using the C-index and time-dependent ROC.
resultsThe 2D/3D MRE-based risk scores incorporating age, platelet count, albumin, and liver stiffness provided better predictive performance in HCC development than three existing clinical risk scores [CAMD (cirrhosis, age, male sex, and diabetes mellitus), PAGE-B (platelet age gender-B), and mPAGE-B (modified platelets, age, gender-hepatitis B)] in the training (C-index: 0.859 and 0.872, respectively, vs 0.762, 0.754 and 0.818, all p value < 0.05) and validation cohorts (C-index: 0.878 and 0.887, respectively, vs 0.815, 0.709 and 0.810, all p value < 0.05). The 2D and 3D MRE-based risk scores provided high negative predictive values in the training and validation cohorts at 3 years (97.8-100.0%) and 5 years (94.6-100.0%) with the two optimal cut-off values of 43.2 and 69.2, respectively, and 56.5 and 71.6, respectively.
conclusionsBoth 2D and 3D MRE-based risk scores may serve as a valuable tool for predication of HCC development for CHB patients and provided superior predictive performance compared to existing clinical scores. KEY POINTS: Question Can MRE be a useful component of a risk score to predict HCC development in CHB patients with sustained virological response? Findings 2D/3D MRE-based stiffness values were independent predictors for HCC development, and the 2D/3D MRE-based risk scores demonstrated better performance than three existing clinical risk scores. Clinical relevance The 2D/3D MRE-based risk scores provide high negative predictive values for HCC development, which may become a noninvasive tool for clinicians to stratify CHB patients for HCC surveillance and to improve early HCC detection and reduce mortality.
Indexed as
Identifiers
40506638What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.